290 related articles for article (PubMed ID: 37392737)
1. TCR-independent CD137 (4-1BB) signaling promotes CD8
Pichler AC; Carrié N; Cuisinier M; Ghazali S; Voisin A; Axisa PP; Tosolini M; Mazzotti C; Golec DP; Maheo S; do Souto L; Ekren R; Blanquart E; Lemaitre L; Feliu V; Joubert MV; Cannons JL; Guillerey C; Avet-Loiseau H; Watts TH; Salomon BL; Joffre O; Grinberg-Bleyer Y; Schwartzberg PL; Lucca LE; Martinet L
Immunity; 2023 Jul; 56(7):1631-1648.e10. PubMed ID: 37392737
[TBL] [Abstract][Full Text] [Related]
2. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
[TBL] [Abstract][Full Text] [Related]
3. CD137 (4-1BB) costimulation of CD8
Otano I; Azpilikueta A; Glez-Vaz J; Alvarez M; Medina-Echeverz J; Cortés-Domínguez I; Ortiz-de-Solorzano C; Ellmark P; Fritzell S; Hernandez-Hoyos G; Nelson MH; Ochoa MC; Bolaños E; Cuculescu D; Jaúregui P; Sanchez-Gregorio S; Etxeberria I; Rodriguez-Ruiz ME; Sanmamed MF; Teijeira Á; Berraondo P; Melero I
Nat Commun; 2021 Dec; 12(1):7296. PubMed ID: 34911975
[TBL] [Abstract][Full Text] [Related]
4. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
5. Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
Kotanides H; Sattler RM; Lebron MB; Carpenito C; Shen J; Li J; Surguladze D; Haidar JN; Burns C; Shen L; Inigo I; Pennello AL; Forest A; Chen X; Chin D; Sonyi A; Topper M; Boucher L; Sharma P; Zhang Y; Burtrum D; Novosiadly RD; Ludwig DL; Plowman GD; Kalos M
Mol Cancer Ther; 2020 Apr; 19(4):988-998. PubMed ID: 32241872
[TBL] [Abstract][Full Text] [Related]
6. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.
Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I
ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557
[TBL] [Abstract][Full Text] [Related]
7. CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice.
Forsberg MH; Ciecko AE; Bednar KJ; Itoh A; Kachapati K; Ridgway WM; Chen YG
J Immunol; 2017 May; 198(10):3857-3868. PubMed ID: 28363905
[TBL] [Abstract][Full Text] [Related]
8. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
10. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8
Aznar MA; Labiano S; Diaz-Lagares A; Molina C; Garasa S; Azpilikueta A; Etxeberria I; Sanchez-Paulete AR; Korman AJ; Esteller M; Sandoval J; Melero I
Cancer Immunol Res; 2018 Jan; 6(1):69-78. PubMed ID: 29133290
[TBL] [Abstract][Full Text] [Related]
11. Direct CD137 costimulation of CD8 T cells promotes retention and innate-like function within nascent atherogenic foci.
Xu MM; Ménoret A; Nicholas SE; Günther S; Sundberg EJ; Zhou B; Rodriguez A; Murphy PA; Vella AT
Am J Physiol Heart Circ Physiol; 2019 Jun; 316(6):H1480-H1494. PubMed ID: 30978132
[TBL] [Abstract][Full Text] [Related]
12. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
13. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
14. IκBα Nuclear Export Enables 4-1BB-Induced cRel Activation and IL-2 Production to Promote CD8 T Cell Immunity.
Lisiero DN; Cheng Z; Tejera MM; Neldner BT; Warrick JW; Wuerzberger-Davis SM; Hoffmann A; Suresh M; Miyamoto S
J Immunol; 2020 Sep; 205(6):1540-1553. PubMed ID: 32817348
[TBL] [Abstract][Full Text] [Related]
15. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
[TBL] [Abstract][Full Text] [Related]
17. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.
Melero I; Sanmamed MF; Glez-Vaz J; Luri-Rey C; Wang J; Chen L
Cancer Discov; 2023 Mar; 13(3):552-569. PubMed ID: 36576322
[TBL] [Abstract][Full Text] [Related]
18. Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
Upadhyaya P; Lahdenranta J; Hurov K; Battula S; Dods R; Haines E; Kleyman M; Kristensson J; Kublin J; Lani R; Ma J; Mudd G; Repash E; Van Rietschoten K; Stephen T; You F; Harrison H; Chen L; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500260
[TBL] [Abstract][Full Text] [Related]
19. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB signaling activates the t cell factor 1 effector/β-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T Cells.
Lee DY; Choi BK; Lee DG; Kim YH; Kim CH; Lee SJ; Kwon BS
PLoS One; 2013; 8(7):e69677. PubMed ID: 23874982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
